Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
2023-03-02 Sale |
2023-03-03 5:10 pm |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
1,088 | $43.88 | $47,741 | 89,953 (Direct) |
View |
2023-01-04 Sale |
2023-01-06 5:39 pm |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
4,838 | $37.82 | $182,982 | 17,629 (Direct) |
View |
2023-01-04 Sale |
2023-01-06 5:32 pm |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
6,673 | $37.21 | $248,302 | 825,240 (Indirect Direct) |
View |
2023-01-04 Sale |
2023-01-06 5:29 pm |
Intellia Therapeutics Inc. | NTLA | Hicks Derek EVP, Chief Business Officer |
1,812 | $37.21 | $67,425 | 17,306 (Direct) |
View |
2023-01-04 Sale |
2023-01-06 5:26 pm |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,574 | $37.21 | $95,779 | 25,687 (Direct) |
View |
2023-01-04 Sale |
2023-01-06 5:23 pm |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
2,427 | $37.21 | $90,309 | 15,404 (Direct) |
View |
2022-07-01 Sale |
2023-01-06 5:21 pm |
Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer |
2,028 | $37.65 | $76,357 | 14,473 (Direct) |
View |
2023-01-04 Sale |
2023-01-06 5:19 pm |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
1,138 | $37.21 | $42,345 | 19,559 (Direct) |
View |
2022-01-01 Sale |
2022-03-04 9:07 pm |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
2,493 | $112.25 | $279,852 | 907,552 (Indirect Direct) |
View |
2022-01-01 Sale |
2022-03-03 8:03 pm |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
1,148 | $112.25 | $128,863 | 42,947 (Direct) |
View |
2022-01-01 Sale |
2022-03-03 8:00 pm |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
1,051 | $112.24 | $117,964 | 48,117 (Direct) |
View |
2022-01-01 Sale |
2022-03-03 7:38 pm |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
1,013 | $112.24 | $113,699 | 36,677 (Direct) |
View |
2021-11-05 Sale |
2021-11-09 6:08 pm |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $132.72 | $318,535 | 188,791 (Direct) |
View |
2021-10-14 Sale |
2021-10-15 7:02 pm |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $128.44 | $308,249 | 191,191 (Direct) |
View |
2021-10-11 Sale |
2021-10-13 4:15 pm |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
2,500 | $119.55 | $298,875 | 27,594 (Direct) |
View |
2021-10-05 Sale |
2021-10-07 5:41 pm |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
10,000 | $130.54 | $1,305,391 | 30,094 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
2023-03-01 Option Award |
2023-03-03 5:10 pm |
N/A 2033-02-28 |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
71,482 | $0 | 89,953 (Direct) |
View |
2023-01-01 Exercise |
2023-01-04 8:38 pm |
2023-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
3,500 | $0 | 29,467 (Direct) |
View |
2023-01-01 Exercise |
2023-01-04 8:36 pm |
2023-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
7,848 | $0 | 847,611 (Direct) |
View |
2023-01-01 Exercise |
2023-01-04 8:33 pm |
2023-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
3,187 | $0 | 34,637 (Direct) |
View |
2023-01-01 Exercise |
2023-01-04 8:29 pm |
2023-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
3,062 | $0 | 23,957 (Direct) |
View |
2022-06-14 Option Award |
2022-06-16 6:46 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | Verwiel Frank Director |
12,885 | $0 | 14,979 (Direct) |
View |
2022-06-14 Option Award |
2022-06-16 6:40 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | Keresty Georgia Director |
12,885 | $0 | 19,409 (Direct) |
View |
2022-06-14 Option Award |
2022-06-16 6:36 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | GOODMAN JESSE Director |
12,885 | $0 | 14,979 (Direct) |
View |
2022-06-14 Option Award |
2022-06-16 6:33 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | FORMELA JEAN FRANCOIS Director |
12,885 | $0 | 14,979 (Direct) |
View |
2022-06-14 Option Award |
2022-06-16 6:26 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | DORSA CAROLINE Director |
12,885 | $0 | 20,389 (Direct) |
View |
2022-06-14 Option Award |
2022-06-16 6:24 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
12,885 | $0 | 14,979 (Direct) |
View |
2022-06-14 Option Award |
2022-06-16 6:22 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | Cohen Fred E Director |
12,885 | $0 | 44,979 (Direct) |
View |
2022-06-14 Option Award |
2022-06-16 6:19 pm |
N/A 2032-06-13 |
Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director |
4,994 | $0 | 12,948 (Direct) |
View |
2022-04-28 Option Award |
2022-05-02 9:49 pm |
N/A 2032-04-27 |
Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director |
19,654 | $0 | 19,654 (Direct) |
View |
2021-06-23 Option Award(A) |
2022-04-14 8:44 pm |
N/A 2031-06-22 |
Intellia Therapeutics Inc. | NTLA | Keresty Georgia Director |
4,103 | $0 | 9,058 (Direct) |
View |
2022-03-01 Option Award |
2022-03-07 7:19 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer |
25,922 | $0 | 31,560 (Direct) |
View |
Ownership |
2022-03-07 7:15 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer |
0 | $0 | 99,888 (Direct) |
View |
2022-03-01 Option Award(A) |
2022-03-04 9:09 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
14,109 | $0 | 14,109 (Direct) |
View |
2022-03-01 Option Award |
2022-03-04 9:07 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
100,931 | $0 | 907,552 (Direct) |
View |
2022-01-01 Exercise |
2022-03-04 9:07 pm |
2022-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO |
7,848 | $0 | 907,552 (Direct) |
View |
2022-03-01 Option Award(A) |
2022-03-04 9:04 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
18,600 | $0 | 18,600 (Direct) |
View |
2022-03-01 Option Award(A) |
2022-03-04 9:01 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
20,203 | $0 | 20,203 (Direct) |
View |
2022-03-01 Option Award(A) |
2022-03-04 8:58 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
20,203 | $0 | 20,203 (Direct) |
View |
2022-03-01 Option Award |
2022-03-03 8:03 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
13,816 | $0 | 42,947 (Direct) |
View |
2022-01-01 Exercise |
2022-03-03 8:03 pm |
2022-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
3,500 | $0 | 42,947 (Direct) |
View |
2022-03-01 Option Award |
2022-03-03 8:00 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
13,816 | $0 | 48,117 (Direct) |
View |
2022-01-01 Exercise |
2022-03-03 8:00 pm |
2022-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
3,187 | $0 | 48,117 (Direct) |
View |
2022-03-01 Option Award |
2022-03-03 7:38 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
12,720 | $0 | 36,677 (Direct) |
View |
2022-01-01 Exercise |
2022-03-03 7:38 pm |
2022-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Goddard Glenn EVP, Chief Financial Officer |
3,062 | $0 | 36,677 (Direct) |
View |
2022-03-01 Option Award |
2022-03-03 7:34 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel |
20,697 | $0 | 30,345 (Direct) |
View |
2022-01-03 Option Award |
2022-01-05 4:15 pm |
N/A 2032-01-02 |
Intellia Therapeutics Inc. | NTLA | Hicks Derek EVP, Chief Business Officer |
44,118 | $0 | 44,118 (Direct) |
View |
2021-11-05 Exercise |
2021-11-09 6:08 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $12.62 | 188,791 (Direct) |
View |
2021-11-05 Exercise |
2021-11-09 6:08 pm |
N/A 2030-04-30 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $0 | 188,791 (Direct) |
View |
2021-10-14 Exercise |
2021-10-15 7:02 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $12.62 | 191,191 (Direct) |
View |
2021-10-14 Exercise |
2021-10-15 7:02 pm |
N/A 2030-04-30 |
Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer |
2,400 | $0 | 191,191 (Direct) |
View |
2021-10-11 Exercise |
2021-10-13 4:15 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
2,500 | $18.83 | 27,594 (Direct) |
View |
2021-10-11 Exercise |
2021-10-13 4:15 pm |
N/A 2030-10-01 |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
2,500 | $0 | 27,594 (Direct) |
View |
2021-10-05 Exercise |
2021-10-07 5:41 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
10,000 | $18.83 | 30,094 (Direct) |
View |
2021-10-05 Exercise |
2021-10-07 5:41 pm |
N/A 2030-10-01 |
Intellia Therapeutics Inc. | NTLA | Crowley John F Director |
10,000 | $0 | 30,094 (Direct) |
View |